On Apr. 25, 2025, Amgen announced a $900 million expansion of its Ohio biotech manufacturing facility in New Albany, becoming the latest in a string of drug makers pledging to increase U.S. capacity amid Trump administration threats of potential import tariffs.

Amgen, based in Thousand Oaks, California, said the plans bring its total investment in central Ohio to more than $1.4 billion, creating 750 jobs.

The Pharmaceutical Research and Manufacturers of America, the industry’s trade group, has said it can take five to 10 years and $2 billion to launch a new U.S. production in part because of regulatory requirements. A study commissioned by the lobbying group found that tariffs could lead to higher drug prices.

The biotechnology company announced in December plans to invest $1 billion to build a second drug substance manufacturing plant in Holly Springs, North Carolina. Amgen also has manufacturing facilities in Massachusetts, Rhode Island, California and Puerto Rico.